The Study on Timolol and Its Potential Phototoxicity Using Chemical, In Silico and In Vitro Methods
Timolol (TIM) is a non-selective ß-adrenergic receptor antagonist used orally for the treatment of hypertension and heart attacks, and topically for treating glaucoma; lately, it has also been used in some specific dermatological problems. In the present study, its photodegradation and potential ris...
Main Authors: | Karolina Lejwoda, Anna Gumieniczek, Agata Filip, Beata Naumczuk |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2024-01-01
|
Series: | Pharmaceuticals |
Subjects: | |
Online Access: | https://www.mdpi.com/1424-8247/17/1/98 |
Similar Items
-
Photodegradation of the H<sub>1</sub> Antihistaminic Topical Drugs Emedastine, Epinastine, and Ketotifen and ROS Tests for Estimations of Their Potent Phototoxicity
by: Anna Gumieniczek, et al.
Published: (2020-06-01) -
EXPERIMENTAL TESTING OF AN IN VIVO METHOD OF PHOTOTOXICITY EVALUATION
by: V. А. Vavilova, et al.
Published: (2018-06-01) -
Validation of a Light Source for Phototoxicity in in vitro Conditions
by: Ivan Iliev, et al.
Published: (2022-06-01) -
Brinzolamide/timolol versus dorzolamide/timolol fixed combinations: A hospital-based, prospective, randomized study
by: Mary S Galose, et al.
Published: (2016-01-01) -
Fortifying angiogenic efficacy of conditioned media using phototoxic‐free blue light for wound healing
by: Sung‐Won Kim, et al.
Published: (2023-05-01)